Mahesh Thirunavukkarasu

Dr. Mahesh Thirunavukkarasu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2015 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
MTMahesh Thirunavukkarasu
Mahesh Thirunavukkarasu
VSVaithinathan Selvaraju
Vaithinathan Selvaraju
LTLeonidas Tapias
Leonidas Tapias
JSJuan A. Sanchez
Juan A. Sanchez
JPJ. Alexander Palesty
J. Alexander Palesty
Nilanjana MaulikNilanjana Maulik
Nilanjana Maulik

1 March 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RLRajesh Lakshmanan
Rajesh Lakshmanan
JCJacob Campbell
Jacob Campbell
GUGopi Ukani
Gopi Ukani
ABAndré O'REilly Beringhs
André O'REilly Beringhs
VSVaithinathan Selvaraju
Vaithinathan Selvaraju
Nilanjana MaulikNilanjana Maulik
Nilanjana Maulik

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
MTMahesh Thirunavukkarasu
Mahesh Thirunavukkarasu
VSVaithinathan Selvaraju
Vaithinathan Selvaraju
NDNageswara Rao Dunna
Nageswara Rao Dunna
JFJocelyn L.C. Foye
Jocelyn L.C. Foye
MJMandip Joshi
Mandip Joshi
NMNilanjana Maulik
Nilanjana Maulik

1 December 2017 in Journal of Surgical Research
Verified
Journal Article
Closed access
RWRickesha L. Wilson
Rickesha L. Wilson
VSVaithinathan Selvaraju
Vaithinathan Selvaraju
RLRajesh Lakshmanan
Rajesh Lakshmanan
MTMahesh Thirunavukkarasu
Mahesh Thirunavukkarasu
JCJacob Campbell
Jacob Campbell
Nilanjana MaulikNilanjana Maulik
Nilanjana Maulik

Verified
Journal Article
Open access
PDF file
AKAndy Kemerley
Andy Kemerley
AGAbhishek Gupta
Abhishek Gupta
MTMahesh Thirunavukkarasu
Mahesh Thirunavukkarasu
MMMonica Maloney Maloney
Monica Maloney Maloney
SBSean Burgwardt
Sean Burgwardt
Nilanjana MaulikNilanjana Maulik
Nilanjana Maulik
The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) virus and the resulting COVID-19 pandemic have had devastating and lasting impact on the global population. Although the main target of the disease is the respiratory tract, clinical outcomes, and research have also shown significant effects of infection on other organ systems. Of interest in this review is the effect of the virus on the cardiovascular system. Complications, including hyperinflammatory syndrome, myocarditis, and cardiac failure, have been documented in the context of COVID-19 infection. These complications ultimately contribute to worse patient outcomes, especially in patients with pre-existing conditions such as hypertension, diabetes, or cardiovascular disease (CVD). Importantly and interestingly, reports have demonstrated that COVID-19 also causes myocardial injury in adults without pre-existing conditions and contributes to systemic complications in pediatric populations, such as the development of multisystem inflammatory syndrome in children (MIS-C). Although there is still a debate over the exact mechanisms by which such complications arise, understanding the potential paths by which the virus can influence the cardiovascular system to create an inflammatory environment may clarify how SARS-CoV-2 interacts with human physiology. In addition to describing the mechanisms of disease propagation and patient presentation, this review discusses the diagnostic findings and treatment strategies and the evolution of management for patients presenting with cardiovascular complications, focusing on disease treatment and prevention.

1 March 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JCJacob D. Campbell
Jacob D. Campbell
RLRajesh Lakshmanan
Rajesh Lakshmanan
VSVaithinathan Selvaraju
Vaithinathan Selvaraju
DADiego Accorsi
Diego Accorsi
DMDavid W. McFadden
David W. McFadden
MTMahesh Thirunavukkarasu
Mahesh Thirunavukkarasu